Richard Simkin - Indivior PLC Chief Officer
| INDV Stock | 11.33 0.15 1.34% |
Executive
Richard Simkin is Chief Officer of Indivior PLC Ordinary
| Address | 10710 Midlothian Turnpike, North Chesterfield, VA, United States, 23235 |
| Phone | 804 379 1090 |
| Web | https://www.indivior.com |
Indivior PLC Management Efficiency
The company has return on total asset (ROA) of 0.1127 % which means that it generated a profit of $0.1127 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.122 %, meaning that it created $0.122 on every $100 dollars invested by stockholders. Indivior PLC's management efficiency ratios could be used to measure how well Indivior PLC manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0 in 2024. Return On Capital Employed is likely to climb to -0.0058 in 2024. At this time, Indivior PLC's Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to climb to about 479.9 M in 2024, despite the fact that Net Tangible Assets are likely to grow to (16.2 M).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Franck Riot | Haleon plc | 56 | |
| Eric Benevich | Neurocrine Biosciences | 59 | |
| Kelly Warfield | Emergent Biosolutions | N/A | |
| Ran Meir | Teva Pharma Industries | N/A | |
| Kyle Gano | Neurocrine Biosciences | 51 | |
| Paul Surdez | Catalent | N/A | |
| Donald Pearl | Bausch Health Companies | N/A | |
| Arthur Shannon | Bausch Health Companies | N/A | |
| Robert Burrows | Emergent Biosolutions | N/A | |
| Haywood Miller | Emergent Biosolutions | N/A | |
| Claire Dickson | Haleon plc | N/A | |
| David JD | Teva Pharma Industries | 61 | |
| Josh Coyle | Bausch Health Companies | N/A | |
| Giedrius Zunda | Alvotech | N/A | |
| Sonya Ghobrial | Haleon plc | 50 | |
| JeanJacques Charhon | Bausch Health Companies | 59 | |
| Eva Gunnlaugsdottir | Alvotech | N/A | |
| Kathleen Fitzpatrick | Bausch Health Companies | N/A | |
| Matthew CPA | Neurocrine Biosciences | 44 | |
| John MBA | Catalent | 69 | |
| Lisa Evoli | Catalent | 54 | |
Management Performance
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.11 |
Indivior PLC Ordinary Leadership Team
Elected by the shareholders, the Indivior PLC's board of directors comprises two types of representatives: Indivior PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Indivior. The board's role is to monitor Indivior PLC's management team and ensure that shareholders' interests are well served. Indivior PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Indivior PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jon Fogle, Chief Officer | ||
| Nina DeLorenzo, Chief Officer | ||
| Vishal Kalia, Support Access | ||
| Jason Thompson, Vice Relations | ||
| Kathryn Hudson, Company Secretary | ||
| Christian Heidbreder, Chief Officer | ||
| Richard Simkin, Chief Officer | ||
| Mark Crossley, CEO Director | ||
| Cynthia Cetani, Chief Officer | ||
| Jeffrey JD, Chief Officer | ||
| Jeffrey Burris, Chief Officer | ||
| Ryan Preblick, CFO Director | ||
| Hillel West, Chief Officer | ||
| Angela MS, Chief Officer |
Indivior Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Indivior PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | 0.31 % | ||||
| Current Valuation | 1.34 B | ||||
| Shares Outstanding | 126.15 M | ||||
| Shares Owned By Insiders | 5.35 % | ||||
| Shares Owned By Institutions | 88.98 % | ||||
| Number Of Shares Shorted | 1.01 M | ||||
| Price To Book | 145.25 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Indivior Stock Analysis
When running Indivior PLC's price analysis, check to measure Indivior PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indivior PLC is operating at the current time. Most of Indivior PLC's value examination focuses on studying past and present price action to predict the probability of Indivior PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indivior PLC's price. Additionally, you may evaluate how the addition of Indivior PLC to your portfolios can decrease your overall portfolio volatility.